HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ StudyIvonne Haffner, Florian Lordick, Katharina Kolbe et al.|Journal of Clinical Oncology|2021Cited by 124
Abstract 2615: Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ studyFlorian Lordick, Christian Wittekind, Ivonne Haffner et al.|Cancer Research|2018Cited by 5
PD-005 Response and resistance factor candidates to HER2 targeted therapy in gastric cancer (GC)Florian Lordick, Christian Wittekind, Ivonne Haffner et al.|Annals of Oncology|2016Cited by 0
Central validation of HER2 status to determine heterogeneity of marker expression in HER2-positive gastric cancer (GC).Ivonne Haffner, Florian Lordick, Birgit Luber et al.|Journal of Clinical Oncology|2017Cited by 0